【ChiCTR1800016581】A Retrospective Study to compare Cost and Effectiveness of Intravenous Patient-Controlled Analgesia (IVPCA) Morphine protocol and Preemptive Multimodal Analgesia Oral Etoricoxib and Oxycontin Protocol for Post Total Knee Replacement Patients
ChiCTR1800016581
结束
/
/
/
2018-05-24
/
/
Total Knee Replacement
A Retrospective Study to compare Cost and Effectiveness of Intravenous Patient-Controlled Analgesia (IVPCA) Morphine protocol and Preemptive Multimodal Analgesia Oral Etoricoxib and Oxycontin Protocol for Post Total Knee Replacement Patients
A Retrospective Study to compare Cost and Effectiveness of Intravenous Patient-Controlled Analgesia (IVPCA) Morphine protocol and Preemptive Multimodal Analgesia Oral Etoricoxib and Oxycontin Protocol for Post Total Knee Replacement Patients
to compare Cost and Effectiveness of Intravenous Patient-Controlled Analgesia (IVPCA) Morphine protocol and Preemptive Multimodal Analgesia Oral Etoricoxib and Oxycontin Protocol for Post Total Knee Replacement Patients.
析因分组（即根据危险因素或暴露因素分组）
回顾性研究
N/A
N/A
香港中文大學威爾士親王醫院麻醉與重症監護部
/
102
/
1990-01-01
1990-01-01
/
Only patients with similar demographics including age, body weight ≥ 44kg,operation, anaesthesia type, medical condition, & postoperative treatment data of both groups who had attended pain management class or pre-operative anesthesia assessment clinic.；
请登录查看Patients who had not attended pain management class or pre-operative anesthesia assessment clinic, non-schedule operation, underwent bilateral TKR, severe psychological illness, active or history of drug abuse, incompliance to either treatment group or contra-indicated to the analgesics used.；
请登录查看香港中文大學威爾士親王醫院麻醉與重症監護部
/
香港中文大學威爾士親王醫院麻醉與重症監護部的其他临床试验
香港中文大學威爾士親王醫院麻醉與重症監護部的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 60
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04